How well does the PCA3–incorporated chun nomogram perform in predicting prostate biopsy outcome among South African men?

Abstract

The incidence of prostate cancer among South African men is just as significant as it is worldwide [1,2]. Although the role of the prostate cancer antigen 3 (PCA3) assay in predicting biopsy outcome has proven beneficial in a South African context [3], the assessment of its role incorporated into a prostate cancer risk calculator has not yet been explored on the continent of Africa. We aimed to assess the performance of the PCA3-incorporated Chun nomogram [4] and to compare its performance with other contemporary risk calculators.